Merck Says Covid Pill Cut Hospitalizations, Deaths by Half

Merck & Co.’s Covid-19 antiviral pill molnupiravir reduced the risk of hospitalization or death by 50% in an interim analysis of a late-stage trial, findings that could give doctors another potent virus-fighting tool.